Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1949 1
1951 1
1953 1
1954 2
1955 5
1956 3
1957 4
1958 5
1959 3
1960 5
1961 4
1962 6
1963 2
1964 4
1965 1
1966 3
1967 1
1968 1
1969 4
1971 2
1972 7
1973 5
1974 4
1975 6
1976 4
1977 6
1978 9
1979 2
1980 4
1981 1
1982 8
1983 3
1984 5
1985 5
1986 5
1987 7
1988 3
1989 5
1990 3
1991 2
1992 4
1993 4
1994 5
1995 7
1996 9
1997 17
1998 7
1999 5
2000 9
2001 5
2002 2
2003 4
2004 3
2005 4
2006 4
2007 9
2008 7
2009 8
2010 11
2011 10
2012 12
2013 11
2014 10
2015 10
2016 19
2017 22
2018 19
2019 18
2020 20
2021 14
Text availability
Article attribute
Article type
Publication date

Search Results

416 results
Results by year
Filters applied: . Clear all
Page 1
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Bumma N, Kaufman JL, Medvedova E, Kovacsovics T, Rosenzweig M, Sanchorawala V, Qin X, Vasey SY, Weiss BM, Vermeulen J, Merlini G, Comenzo RL. Palladini G, et al. Among authors: rosenzweig m. Blood. 2020 Jul 2;136(1):71-80. doi: 10.1182/blood.2019004460. Blood. 2020. PMID: 32244252 Free PMC article. Clinical Trial.
Abuse Potential of Pregabalin: A Systematic Review.
Schjerning O, Rosenzweig M, Pottegård A, Damkier P, Nielsen J. Schjerning O, et al. Among authors: rosenzweig m. CNS Drugs. 2016 Jan;30(1):9-25. doi: 10.1007/s40263-015-0303-6. CNS Drugs. 2016. PMID: 26767525 Review.
ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells.
Singh L, Muise ES, Bhattacharya A, Grein J, Javaid S, Stivers P, Zhang J, Qu Y, Joyce-Shaikh B, Loboda A, Zhang C, Meehl M, Chiang DY, Ranganath SH, Rosenzweig M, Brandish PE. Singh L, et al. Among authors: rosenzweig m. Mol Cancer Res. 2021 Apr;19(4):702-716. doi: 10.1158/1541-7786.MCR-20-0622. Epub 2020 Dec 28. Mol Cancer Res. 2021. PMID: 33372059
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SH, Salgia R, Brennan T, Chalmers ZR, Jaeger S, Huang A, Elvin JA, Erlich R, Fichtenholtz A, Gowen KA, Greenbowe J, Johnson A, Khaira D, McMahon C, Sanford EM, Roels S, White J, Greshock J, Schlegel R, Lipson D, Yelensky R, Morosini D, Ross JS, Collisson E, Peters M, Stephens PJ, Miller VA. Frampton GM, et al. Among authors: rosenzweig m. Cancer Discov. 2015 Aug;5(8):850-9. doi: 10.1158/2159-8290.CD-15-0285. Epub 2015 May 13. Cancer Discov. 2015. PMID: 25971938 Free article.
Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Schrock AB, Frampton GM, Suh J, Chalmers ZR, Rosenzweig M, Erlich RL, Halmos B, Goldman J, Forde P, Leuenberger K, Peled N, Kalemkerian GP, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH. Schrock AB, et al. Among authors: rosenzweig m. J Thorac Oncol. 2016 Sep;11(9):1493-502. doi: 10.1016/j.jtho.2016.06.004. Epub 2016 Jun 22. J Thorac Oncol. 2016. PMID: 27343443 Free article.
Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting.
Viola D, Dona A, Caserta E, Troadec E, Besi F, McDonald T, Ghoda L, Gunes EG, Sanchez JF, Khalife J, Martella M, Karanes C, Htut M, Wang X, Rosenzweig M, Chowdhury A, Sborov D, Miles RR, Yazaki PJ, Ebner T, Hofmeister CC, Forman SJ, Rosen ST, Marcucci G, Shively J, Keats JJ, Krishnan A, Pichiorri F. Viola D, et al. Among authors: rosenzweig m. Leukemia. 2021 Jan;35(1):189-200. doi: 10.1038/s41375-020-0810-4. Epub 2020 Apr 16. Leukemia. 2021. PMID: 32296125 Free PMC article.
Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting.
He J, Abdel-Wahab O, Nahas MK, Wang K, Rampal RK, Intlekofer AM, Patel J, Krivstov A, Frampton GM, Young LE, Zhong S, Bailey M, White JR, Roels S, Deffenbaugh J, Fichtenholtz A, Brennan T, Rosenzweig M, Pelak K, Knapp KM, Brennan KW, Donahue AL, Young G, Garcia L, Beckstrom ST, Zhao M, White E, Banning V, Buell J, Iwanik K, Ross JS, Morosini D, Younes A, Hanash AM, Paietta E, Roberts K, Mullighan C, Dogan A, Armstrong SA, Mughal T, Vergilio JA, Labrecque E, Erlich R, Vietz C, Yelensky R, Stephens PJ, Miller VA, van den Brink MR, Otto GA, Lipson D, Levine RL. He J, et al. Among authors: rosenzweig m. Blood. 2016 Jun 16;127(24):3004-14. doi: 10.1182/blood-2015-08-664649. Epub 2016 Mar 10. Blood. 2016. PMID: 26966091 Free PMC article.
Response.
Lindell KO, Rosenzweig MQ, Pilewski J, Hoffman LA, Gibson K, Kaminski N. Lindell KO, et al. Among authors: rosenzweig mq. Chest. 2015 Aug;148(2):e57-e58. doi: 10.1378/chest.15-0772. Chest. 2015. PMID: 26238840 Free PMC article. No abstract available.
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
Krishnan A, Kapoor P, Palmer JM, Tsai NC, Kumar S, Lonial S, Htut M, Karanes C, Nathwani N, Rosenzweig M, Sahebi F, Somlo G, Duarte L, Sanchez JF, Auclair D, Forman SJ, Berdeja JG. Krishnan A, et al. Among authors: rosenzweig m. Leukemia. 2018 Jul;32(7):1567-1574. doi: 10.1038/s41375-018-0038-8. Epub 2018 Feb 23. Leukemia. 2018. PMID: 32082000 Free PMC article.
Daratumumab induces CD38 internalization and impairs myeloma cell adhesion.
Ghose J, Viola D, Terrazas C, Caserta E, Troadec E, Khalife J, Gunes EG, Sanchez J, McDonald T, Marcucci G, Kaur B, Rosenzweig M, Keats J, Rosen S, Krishnan A, Satoskar AR, Hofmeister CC, Pichiorri F. Ghose J, et al. Among authors: rosenzweig m. Oncoimmunology. 2018 Jul 23;7(10):e1486948. doi: 10.1080/2162402X.2018.1486948. eCollection 2018. Oncoimmunology. 2018. PMID: 30288349 Free PMC article.
416 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page